Cipher Pharma Acquires Canadian Rights To Vaniqa & Actikerall - Quick Facts

(RTTNews) - Cipher Pharmaceuticals Inc. (CPHR, CPH.TO) announced it has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa and Actikerall from Almirall S. A., a Spanish pharmaceutical company.

VANIQA is a prescription cream clinically proven to reduce the growth of unwanted facial hair in women. Actikerall is indicated for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis, a pre-cancerous patch of thick, scaly, or crusty skin. Both products have been approved by Health Canada.

Almirall will receive an upfront payment of C$0.45 million and is eligible for certain milestones from product sales in Canada. Almirall will supply finished product to Cipher.